beta-N-Acetylhexosaminidases
"beta-N-Acetylhexosaminidases" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A hexosaminidase specific for non-reducing N-acetyl-D-hexosamine residues in N-acetyl-beta-D-hexosaminides. It acts on GLUCOSIDES; GALACTOSIDES; and several OLIGOSACCHARIDES. Two specific mammalian isoenzymes of beta-N-acetylhexoaminidase are referred to as HEXOSAMINIDASE A and HEXOSAMINIDASE B. Deficiency of the type A isoenzyme causes TAY-SACHS DISEASE, while deficiency of both A and B isozymes causes SANDHOFF DISEASE. The enzyme has also been used as a tumor marker to distinguish between malignant and benign disease.
| Descriptor ID |
D001619
|
| MeSH Number(s) |
D08.811.277.450.483.180
|
| Concept/Terms |
beta-N-Acetylhexosaminidases- beta-N-Acetylhexosaminidases
- beta N Acetylhexosaminidases
- N-Acetyl-beta-D-hexosaminidase
- N Acetyl beta D hexosaminidase
- beta-N-Acetyl-hexosaminidase
- beta N Acetyl hexosaminidase
- beta-N-Acetylhexosaminidase
- beta N Acetylhexosaminidase
- beta-Hexosaminidase
- beta Hexosaminidase
- beta-N-Acetyl-D-hexosaminidase
- beta N Acetyl D hexosaminidase
|
Below are MeSH descriptors whose meaning is more general than "beta-N-Acetylhexosaminidases".
Below are MeSH descriptors whose meaning is more specific than "beta-N-Acetylhexosaminidases".
This graph shows the total number of publications written about "beta-N-Acetylhexosaminidases" by people in this website by year, and whether "beta-N-Acetylhexosaminidases" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 0 | 2 | 2 |
| 2007 | 0 | 3 | 3 |
| 2019 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "beta-N-Acetylhexosaminidases" by people in Profiles.
-
Cavalcante PAM, Alenina N, Budu A, Freitas-Lima LC, Alves-Silva T, Agudelo JSH, Qadri F, Camara NOS, Bader M, Ara?jo RC. Nephropathy in Hypertensive Animals Is Linked to M2 Macrophages and Increased Expression of the YM1/Chi3l3 Protein. Mediators Inflamm. 2019; 2019:9086758.
-
Soule BP, Brown JM, Kushnir-Sukhov NM, Simone NL, Mitchell JB, Metcalfe DD. Effects of gamma radiation on FcepsilonRI and TLR-mediated mast cell activation. J Immunol. 2007 Sep 1; 179(5):3276-86.
-
Mora AL, Torres-González E, Rojas M, Xu J, Ritzenthaler J, Speck SH, Roman J, Brigham K, Stecenko A. Control of virus reactivation arrests pulmonary herpesvirus-induced fibrosis in IFN-gamma receptor-deficient mice. Am J Respir Crit Care Med. 2007 Jun 01; 175(11):1139-50.
-
Lee JP, Jeyakumar M, Gonzalez R, Takahashi H, Lee PJ, Baek RC, Clark D, Rose H, Fu G, Clarke J, McKercher S, Meerloo J, Muller FJ, Park KI, Butters TD, Dwek RA, Schwartz P, Tong G, Wenger D, Lipton SA, Seyfried TN, Platt FM, Snyder EY. Stem cells act through multiple mechanisms to benefit mice with neurodegenerative metabolic disease. Nat Med. 2007 Apr; 13(4):439-47.
-
Kuenzler KA, Pearson PY, Schwartz MZ. Hepatocyte growth factor pretreatment reduces apoptosis and mucosal damage after intestinal ischemia-reperfusion. J Pediatr Surg. 2002 Jul; 37(7):1093-7; discussion 1093-7.
-
Moody DB, Briken V, Cheng TY, Roura-Mir C, Guy MR, Geho DH, Tykocinski ML, Besra GS, Porcelli SA. Lipid length controls antigen entry into endosomal and nonendosomal pathways for CD1b presentation. Nat Immunol. 2002 May; 3(5):435-42.